Solara Active Pharma Sciences Limited (BOM:541540)

BOM:541540 Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	38.7	39.5	84.4	87.3	463.8	1,977
Cash & Short-Term Investments	38.7	39.5	84.4	87.3	463.8	1,977
Cash Growth	-36.24%	-53.20%	-3.32%	-81.18%	-76.54%	252.77%
Accounts Receivable	3,423	3,266	3,485	5,370	4,897	4,839
Other Receivables	130.6	540.6	481.5	375	619.7	572.8
Receivables	3,553	3,807	3,970	6,071	6,032	5,428
Inventory	3,687	3,179	3,597	5,581	5,756	2,950
Prepaid Expenses	-	162.3	114.2	99.9	84.1	156.5
Other Current Assets	697.4	100	241.8	36.2	57.2	65.2
Total Current Assets	7,977	7,287	8,008	11,875	12,393	10,576
Property, Plant & Equipment	10,706	10,765	11,142	11,591	11,374	9,992
Long-Term Investments	17	17	17	17	4.2	4.2
Goodwill	3,649	3,649	3,651	3,651	3,651	3,651
Other Intangible Assets	248.2	298	425.6	543.5	679.4	799.8
Long-Term Deferred Tax Assets	-	-	-	785.6	551.4	256.1
Other Long-Term Assets	337.5	302.4	266.4	529.9	794	855
Total Assets	22,934	22,318	23,510	28,993	29,450	26,136
Accounts Payable	2,880	2,486	3,130	3,059	2,760	3,093
Accrued Expenses	22.3	174.5	98.4	92.8	85.9	61.7
Short-Term Debt	-	5,729	7,603	6,488	6,099	3,609
Current Portion of Long-Term Debt	5,385	893	1,333	1,173	1,316	912
Current Portion of Leases	29	22.5	5.1	5.5	21	20.5
Current Income Taxes Payable	0.1	0.1	0.1	0.1	3.3	1.4
Current Unearned Revenue	-	7.8	157.3	74.3	179.8	152.7
Other Current Liabilities	387.6	128	102	119.5	169	37.4
Total Current Liabilities	8,703	9,441	12,429	11,011	10,634	7,887
Long-Term Debt	848.8	1,139	1,058	2,351	2,830	1,548
Long-Term Leases	198.3	177.7	116.1	111.5	107	117.7
Long-Term Unearned Revenue	-	-	-	-	231.3	284.9
Pension & Post-Retirement Benefits	505.3	489.2	435.9	383.6	275.8	252
Other Long-Term Liabilities	103.9	102.7	105	110.9	99.1	117.8
Total Liabilities	10,360	11,349	14,144	13,968	14,178	10,208
Common Stock	444.7	402.5	360	360	360	359.3
Additional Paid-In Capital	-	13,687	12,160	12,160	12,160	12,117
Retained Earnings	-	-3,156	-3,175	2,493	2,737	3,389
Comprehensive Income & Other	12,103	9.6	-6	-11.3	-8.8	20.3
Total Common Equity	12,548	10,942	9,339	15,002	15,249	15,885
Minority Interest	26.7	26.7	26.7	22.4	23.1	42.4
Shareholders' Equity	12,575	10,969	9,366	15,025	15,272	15,928
Total Liabilities & Equity	22,934	22,318	23,510	28,993	29,450	26,136
Total Debt	6,461	7,961	10,115	10,129	10,374	6,207
Net Cash (Debt)	-6,422	-7,921	-10,031	-10,041	-9,910	-4,230
Net Cash Per Share	-195.11	-198.52	-262.55	-278.95	-275.72	-123.29
Filing Date Shares Outstanding	42.8	48.05	36	36	36	35.93
Total Common Shares Outstanding	42.8	48.05	36	36	36	35.93
Working Capital	-726.9	-2,154	-4,421	864.1	1,759	2,689
Book Value Per Share	293.20	227.72	259.45	416.77	423.62	442.12
Tangible Book Value	8,651	6,995	5,263	10,808	10,918	11,435
Tangible Book Value Per Share	202.14	145.58	146.20	300.25	303.32	318.25
Land	-	782.6	782.6	782.6	782.5	773
Buildings	-	3,300	3,283	3,172	2,918	2,727
Machinery	-	9,129	9,032	8,948	8,064	7,441
Construction In Progress	-	2,801	2,564	2,385	2,387	879.8
Leasehold Improvements	-	37.1	37.1	159.2	150	146.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.